Glenmark becomes the First Company in India to launch Teneligliptin + Dapagliflozin Fixed Dose Combination, for Adults with Type 2 Diabetes, having Comorbidities
MUMBAI, 23 OCTOBER, 2022 (GPN): Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven global pharmaceutical company, became the first to launch Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed dose combination (FDC)for the treatment of adult patients with type 2…







